Healthcare provider profile · identity verified

Reuben M Farris, MD

Allopathic & Osteopathic Physicians|General Practice · CHULA VISTA, CA · NPI 1699749911

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Reuben M Farris, MD received $71.61 in general payments during 2025 across 3 reported records.

Gilead Sciences, Inc. accounted for 81.1% of that reported general-payment amount.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$71.61

3 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Gilead Sciences, Inc.	Unresolved — no canonical attribution shown	$58.05	81.1%	2	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$13.56	18.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$71.61	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	54	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	469	153
Rosuvastatin Calcium	Rosuvastatin Calcium	284	86
Amlodipine Besylate	Amlodipine Besylate	262	83
Metformin Hcl	Metformin Hcl	260	88
Levothyroxine Sodium	Levothyroxine Sodium	242	75
Losartan Potassium	Losartan Potassium	224	80
Lisinopril	Lisinopril	193	61
Tamsulosin Hcl	Tamsulosin Hcl	140	44
Gabapentin	Gabapentin	137	56
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	129	24
Pantoprazole Sodium	Pantoprazole Sodium	129	46
Lorazepam	Lorazepam	128	30
Metoprolol Tartrate	Metoprolol Tartrate	115	34
Omeprazole	Omeprazole	109	44
Tramadol Hcl	Tramadol Hcl	100	30
Alendronate Sodium	Alendronate Sodium	90	30
Hydrochlorothiazide	Hydrochlorothiazide	89	31
Meloxicam	Meloxicam	89	23
Jardiance	Empagliflozin	88	27
Eliquis	Apixaban	86	21
Albuterol Sulfate Hfa	Albuterol Sulfate	84	32
Furosemide	Furosemide	84	33
Glimepiride	Glimepiride	79	24
Alprazolam	Alprazolam	77	19
Montelukast Sodium	Montelukast Sodium	77	22
Zolpidem Tartrate	Zolpidem Tartrate	71	21
Benazepril Hcl	Benazepril Hcl	68	17
Diclofenac Sodium	Diclofenac Sodium	68	25
Simvastatin	Simvastatin	68	24
Atenolol	Atenolol	67	21
Famotidine	Famotidine	59	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	19
Metoprolol Succinate	Metoprolol Succinate	56	21
Ozempic	Semaglutide	54	suppressed
Duloxetine Hcl	Duloxetine Hcl	52	22
Farxiga	Dapagliflozin Propanediol	52	13
Trazodone Hcl	Trazodone Hcl	52	19
Finasteride	Finasteride	51	18
Ibuprofen	Ibuprofen	51	19
Mounjaro	Tirzepatide	49	suppressed
Pregabalin	Pregabalin	49	18
Fluticasone Propionate	Fluticasone Propionate	47	22
Azithromycin	Azithromycin	46	40
Clopidogrel	Clopidogrel Bisulfate	45	15
Naproxen	Naproxen	44	15
Oxycodone Hcl	Oxycodone Hcl	44	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	44	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	42	suppressed
Trulicity	Dulaglutide	41	11
Valsartan	Valsartan	41	14
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	40	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Citalopram Hbr	Citalopram Hydrobromide	38	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	15
Sertraline Hcl	Sertraline Hcl	38	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	38	14
Escitalopram Oxalate	Escitalopram Oxalate	37	11
Glipizide	Glipizide	37	11
Ropinirole Hcl	Ropinirole Hcl	37	11
Carvedilol	Carvedilol	36	12
Ramipril	Ramipril	36	11
Triamcinolone Acetonide	Triamcinolone Acetonide	36	18
Allopurinol	Allopurinol	34	11
Spironolactone	Spironolactone	34	16
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	33	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	31	27
Januvia	Sitagliptin Phosphate	31	14
Nifedipine Er	Nifedipine	30	11
Baclofen	Baclofen	29	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	29	suppressed
Enalapril Maleate	Enalapril Maleate	29	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	29	suppressed
Mirtazapine	Mirtazapine	28	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	24
Amoxicillin	Amoxicillin	26	12
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	26	suppressed
Cephalexin	Cephalexin	26	17
Hydroxyzine Hcl	Hydroxyzine Hcl	26	11
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Nebivolol Hcl	Nebivolol Hcl	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	11
Prednisone	Prednisone	23	13
Lovastatin	Lovastatin	22	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	22	suppressed
Potassium Chloride	Potassium Chloride	22	suppressed
Cilostazol	Cilostazol	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	21	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Latanoprost	Latanoprost	19	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Temazepam	Temazepam	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Letrozole	Letrozole	15	suppressed
Morphine Sulfate Er	Morphine Sulfate	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Metformin Hcl Er	Metformin Hcl	14	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Bumetanide	Bumetanide	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Estradiol	Estradiol	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Ketoconazole	Ketoconazole	13	11
Memantine Hcl	Memantine Hcl	13	suppressed
Minoxidil	Minoxidil	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	12
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Guanfacine Hcl	Guanfacine Hcl	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Linzess	Linaclotide	11	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$71.61 · 3 records	Gilead Sciences, Inc.	—	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error